Event in Progress:
Discover the latest content that has just been published on Research Tree
All three divisions were negatively impacted by a triad of lower volumes and prices, and FX headwinds – earlier than we had expected. Interestingly, only volumes took their toll on profitability and the margin was slightly higher. This was unlike the scenario of some years ago, when Solvay saw collapsing margins in comparable conditions. The Q3 figures were a significant miss relative to our estimates (sales: -11.8%; adjusted EBITDA: -7.0% – consensus: sales: -9.2%; adjusted EBITDA: 1.4%).
Companies: Solvay (SOLB:EBR)Solvay SA (SOLB:BRU)
AlphaValue
Solvay was not able to decouple from the lower overall demand across the chemicals industries, but the company is well positioned to defend its margins at the group level. This allowed the management to confirm its FY guidance with a somewhat more upbeat view on FCF. This may look like an easy task given that >50% has already been booked, but the second semester could become challenging. The revenue line was a -2.9% miss to the consensus although the adjusted EBITDA was a +3.2% beat.
Solvay is now a completely different company than some years ago. Profitability is also stronger during cold weather although things are becoming more difficult as higher sales prices cannot always compensate for lower volumes. All in all, the strong beat on profitability relative to our estimates (+17.0%; consensus: +14.9%) was a pleasant surprise. he company-calculated FCF however missed our expectations by -30.9%.
Solvay’s management achieved a great deal in the 2019-22 period, having successfully navigated the pandemic and the ensuing challenges. By increasing profitability, many other KPIs improved (leverage, ROCE), which now enables the separation of the company. Having covered the company for many years, this seems too good to be true. Solvay reported another quarter beat of AV and the street’s expectations, but 2023 will be a more challenging year with a strong focus on margin preservation.
After some preliminary figures, it was clear Q3 was a strong quarter. Now the future outlook is coming into focus and the management will need to provide some – at least – qualitative insights so as to manage expectations, which could go in two directions. The reported figures were not much of a surprise. As expected, Materials continued its recovery and all divisions enjoyed strong pricing power. The top line beat to our estimates was +11.1% (consensus: +10.9%) and +13.2% (consensus: +20.0%)
The management raised the FY guidance on the back of the strong Q2 coming in in-line with our expectations after the release of preliminary figures, despite being more optimistic at the adjusted EBITDA level. Nevertheless, Alphavalue and the consensus had been far too conservative on the Q2, forcing the company to release preliminary figures earlier this month. We were strongly beaten at the top-line (+18.5%; consensus: +12.2%) and by +30.1% (consensus: +26.5%) at adjusted EBITDA level.
Companies: Solvay SA (0NZR:LON)Solvay SA (SOLB:BRU)
Solvay’s Q1 beat our moderate expectations by +17.8% (sales) and +25.6% (adjusted EBITDA), but beating consensus by +10.6% (sales) and +17.7% (adjusted EBITDA) without ‘ringing’ the preliminary (figures) bell is somewhat annoying. The company sailed ahead of the cost curve, delivering a positive pricing delta, something which added a major building block to the adjusted EBITDA improvement. One positive point is that the higher products did not wipe out volumes.
It sounds like a great plan to separate Solvay’s diversified businesses into two. We do not fully understand why certain businesses ended up in one or the other, even after listening to the conference call. The overriding principle seems to be Value Creation. Taking on a different angle, this unexpected move seems to be an acceleration of Solvay’s historic portfolio rotation story. In the end, it will provide more clarity to shareholders.
Solvay’s figures were only a slight beat to our top-line (+1.4%; consensus: +1.9%) and adjusted EBITDA (+1.9%; consensus: +2.4%) estimates. Interestingly, the beat in IFRS EBIT was even stronger (+15.9%; consensus: +10.9%). FCF declined, but was above the guided level, likewise the adjusted FY EBITDA. Given the 2022 guidance includes some moving parts, management shared many insights and therefore it looks quite achievable in our view.
Solvay released consensus-beating (sales: +6.8%; adjusted EBITDA: +5.1%) Q3 figures, which were driven by all divisions, of which Materials was a bit of a surprise. The latter could increase its margin, but other divisions could only protect them. The updated guidance looks very achievable and the strong Q3 results might make it look cautious. We assume the steep increase in energy prices as well as raw material costs have not full materialised in Q3.
The good news is that Solvay’s Q2 report was not exceptional as the beats to consensus figures were not too strong (sales: +2.7%; adjusted EBITDA: +6.0%). Except for aerospace, all customers showed vital signs and future business prospects led management to the conclusion to lift FY guidance. The weak FCF performance make us wonder if the right measures are in place as NWC flows clearly swung.
Solvay had a very good start, reporting adjusted (!) EBITDA above pre-crisis levels. In the light of reality, the ugly scratches of the portfolio measures obviously weighed on profitability. Nevertheless, we are a bit more optimistic for the company, not just because our estimates were beaten by +5% (sales) and by +10% on the adjusted EBITDA (consensus: +2% and +11%), but the company beat its own estimates by +9%.
Solvay’s cost-cutting initiatives have been successful and protected the company’s profitability in this challenging environment. The reported figures were slightly ahead of consensus on the adjusted profitability level and the miss to the top line was not too meaningful. Our expectations have been clearly beaten on the profitability level. More interesting seems to us the potential change in Solvay’s esteem. ESG commitments have been enlarged under the aegis of the GROW initiative underpinnin
Solvay’s Q3 did not reflect any recovery at the divisional level in its businesses. All divisions recorded double-digit volume declines, especially Materials. This also had a negative impact on profitability, to which adverse FX developments have to be added. Q3 came in weaker than expected, especially in Materials, but the reported figures were above street expectations.
Companies: Solvay SA
Solvay’s management has already indicated weak first months in Q2 but, since then, some of the businesses have caught up. However, the Q2 figures were a notch weaker than feared by consensus, but slightly above our expectations. Management did not provide a detailed outlook, but shed some light on its FY challenges (cost savings). This does not make us too enthusiastic about the coming quarters.
Research Tree provides access to ongoing research coverage, media content and regulatory news on Solvay SA. We currently have 49 research reports from 3 professional analysts.
Strix has reported FY23 results to 31 December 2023 with adjusted PAT of £20.1m, in line with our updated forecast and company guidance provided in January. Revenue grew 35.2% to £144.6m, benefitting from the full year inclusion of the Billi acquisition, albeit slightly below our forecast of £151.0m. Its core Kettle Controls division also performed robustly, growing 2.7%, ahead of the broader market and indicating market share gain. Recent acquisitions have noticeably improved the Group’s growth
Companies: Strix Group PLC
Zeus Capital
Companies: Yu Group PLC
Liberum
Companies: FOG PEB KBT EMR TIME GETB JNEO
Cavendish
Cohort announces that its subsidiary SEA (Systems Engineering and Assessment Ltd.) has been awarded a major contract by the UK’s Ministry of Defence to provide Electronic Warfare Counter Measures (Increment 1a) (EWCM 1a) to the Royal Navy with a total value of at least £135m. This includes provision and support of SEA’s Trainable Decoy Launcher System, Ancilia. At the FY 24 interim results Cohort had commented on an overall “increased tempo” of order intake. The Group reported a closing order b
Companies: Cohort plc
Equity Development
The focus of Hardman & Co Research is on the nine quoted Infrastructure Investment Companies (IICs) and on the 22 Renewable Energy Infrastructure Funds (REIFs): the stocks analysed are all members of the Association of Investment Companies (AIC). We are updating our publication of January 2023, assessing both the lacklustre share price performances during 2023 and the key issues, including interest rates, inflation and power prices. As a 31-strong group, its combined market capitalisation is no
Companies: AEIT ROOF DGI9 INPP GSF SEIT USFP HICL ORIT BSIF TRIG NESF SEQI HEIT GRP GCP FSFL 3IN AERI PINT RNEW BBGI GSEO DORE TENT GRID CORD HGEN AEET
Hardman & Co
Companies: Luceco PLC
Positives emerged, particularly in H2, as the recovery commenced within the kettle controls market. Billi was the architect of the revenue improvement, with LAICA also delivering a double-digit increase in the top line. Margins improved, notwithstanding a change in the mix. Encouragingly, investor concerns on debt were allayed with the careful management of cash, and latterly as bankers raised the net debt/EBITDA covenant to 2.75x. With further emphasis on costs and cash conservation and a lik
Quadrise continues to advance towards commercial revenues for its innovative fuel and biofuel technologies, with each of its projects approaching key milestones in 2024. Preparatory steps for the MSC Shipmanagement (MSC) fuel trials are now complete and fuel supply agreements are nearing finalisation. Quadrise will achieve its first licensing revenues on the successful completion of Valkor’s project financing (timing uncertain). Quadrise also successfully concluded its Morocco trial, paving the
Companies: Quadrise PLC
Edison
Companies: FOG TND BVXP ACC HDD
Companies: Flowtech Fluidpower plc
Judges Scientific is a group involved in the buy and build of scientific instrumentation businesses. Testament to the strength of its highly engineered offer and global diversified customer base, total revenue increased an impressive 20.2% to £136.1m (organic +15%), with adj. PBT +7.5% to £31.7m (FY2022: £28.3m), 3.1% ahead of our estimate of £30.5m. Fully diluted (FD) adjusted EPS increased a more muted 2.6% (impacted by anticipated tax headwinds) to 368.5p (basic adj EPS 374.5p), 3.4% ahead of
Companies: Judges Scientific plc
WHIreland
Companies: Michelmersh Brick Holdings PLC
Canaccord Genuity
Companies: BILN IGP RBN SBTX
Gelion has reported in line H1 FY24 results that demonstrate continued strong cash management and steady progress in its pursuit of next generation lithium-sulphur battery technologies. Encouraging early test results justify last year’s IP acquisitions and validate Gelion’s Li-S battery technology plan, with additional progress expected to be reported in H2 alongside its pursuit of a strategic partner for its planned Advanced Commercial Prototyping Centre (ACPC) facility in Australia. There is a
Companies: Gelion PLC
Forterra’s FY23 (to 31 December) earnings were slightly higher than guidance, which was raised in January, with resilient pricing partly offsetting a steep fall in demand among its main end users, large housebuilders. Our estimates are broadly unchanged, other than reflecting a more conservative stance on the final dividend. Despite a cautious tone in the outlook statement, we believe the largest housebuilders may now rebound more strongly than smaller peers.
Companies: Forterra Plc
Progressive Equity Research
Share: